ReviewJournal of clinical and experimental hematopathology : JCEH2025
Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.
Review in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.Frontiers in immunology · 2026Pooled it
- Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell-associated neurotoxicity on day 355 of epcoritamab therapy: a case report.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of chemotherapy for relapsed/refractory diffuse large B-cell lymphoma remains inadequate. Recent advances in T-cell engaging therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), aim to overcome chemotherapy resistance. BsAbs targeting CD20/CD3, such as epcoritamab, glofitamab, mosunetuzumab, and odronextamab, are rapidly progressing toward widespread clinical application. This review summarizes the clinical efficacy of each BsAb and highlights the need for careful management of adverse events, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Although monotherapy remains the standard approach, clinical trials are exploring earlier-line use and combination strategies to further enhance outcomes. Particular attention is given to predictive biomarkers of response and mechanisms of resistance, including target antigen loss, tumor histology, prior therapies, intratumoral and peripheral T-cell status, and the emerging role of minimal residual disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.